Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786810 · ClinicalTrials.gov registry record · Phase 2
Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
A Phase 2 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02786810 is a Phase 2 study that has completed, run by University of Tennessee. The registered enrollment target is 10 participants.
The verdict
NCT02786810, a Phase 2 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.
Interventions
- DRUG Sulfur hexafluoride type-a lipid microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02786810
The ClinicalTrials.gov registry entry for NCT02786810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sulfur hexafluoride type-a lipid microspheres is the first listed.
NCT02786810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02786810 about?
NCT02786810 is a clinical study titled "Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy". The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.
What is the current status of trial NCT02786810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02786810?
The interventions under investigation include: Sulfur hexafluoride type-a lipid microspheres (DRUG).
Who is sponsoring clinical trial NCT02786810?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.